The Regulatory Affairs Professionals Society (RAPS) is stepping up its presence in Europe and expanding its European team in response to growing membership demand from those involved with the regulation of healthcare and related products. In the last 12 months, the largest global organization for regulatory professionals in the healthcare, medical device, biologic and pharmaceutical sectors has reportedly seen its European member base grow by approximately 19 per cent to more than 1,500 members across 29 countries. RAPS plans to invest more than €2 million over three years implementing a strategic growth plan in Europe that includes launching new events and resources to serve the needs of regulatory professionals in the region. The investment program includes a substantial increase in staff resources for European members and a series of European events including a RAPS Roadshow: ‘Examining the New European Medical Device Regulations’ on 4 May in Munich and a workshop ‘EU Regulatory Essentials, Medical Device and In Vitro Diagnostics: Transitioning from Current Directives to New Regulations’ on July 4-5 in Brussels.
FDA Approves Hikma’s Generic GLP-1 Agonist for Type 2 Diabetes
December 24th 2024Approval marks the first generic version of liraglutide injection, referencing Victoza, for improving glycemic control in adults and children aged 10 years and older with type 2 diabetes, alongside diet and exercise.